Podcasts about Baseline

Stuart Knight has written, produced and starred in shows that have been seen by over one million people, has written best selling books and is the founder of The Human Connection Group. Top 3 Value Bombs 1. The more that you experiment, the more successful you will become. Throw everything at the wall and see what sticks and if it falls off the wall, figure out a way to make it stick. 2. If it is a feeling , we connect but if it's a thinking, we did not connect. 3. Don't be afraid to ask the big question because those big questions will lead to big answers and big answers lead to big relationships. Deeper Connection. With Others.​ With Yourself. The world's biggest resource for people harnessing the power of human connection - The Human Connection Group Sponsors ThriveTime Show Become the next success story, schedule a free consultation and request tickets to join Football Star, Tim Tebow and President Trump's Son, Eric Trump at Clay Clark's next business conference today at: ThrivetimeShow.com/eofire ZipRecruiter Enjoy the benefits of speed hiring with new ZipIntro! Only from ZipRecruiter. Post jobs today, talk to qualified candidates tomorrow. Try ZipIntro for free at ZipRecruiter.com/fire

Charles Schwab's Nathan Peterson says this week was "relatively muted" compared to last week, though there's plenty of volatility moving markets. He expects a rally once the Trump administration reaches a deal with the first round of countries, expecting it to set a baseline for other nations. However, he notes the SPX continues to trade at 24x forward P/E, leaving room for more valuation compression.======== Schwab Network ========Empowering every investor and trader, every market day.Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/About Schwab Network - https://schwabnetwork.com/about

This 2-part podcast was inspired by a Solo Cleaning School Elite member, Dave Reeks. Dave started implementing the ISO Model in early 2022, operating The Finest Clean in South Wales, Australia. I am so proud of his diligence and commitment. Dave has grown from an Initializer to the Stabilizer phase of the ISO Model in 6 months. I recently did an Optimizer's Workshop with him to help him hit his next goal. He is a male solo cleaner like I was and growing quickly with almost 20 house cleaning customers in a short time. Dave recognized the need to keep his body operating at peak performance and wondered if I had any tips for other solo cleaners. Thank you Dave for this question! Yes! I do. I was a solo cleaner from age 28 to 44. There have been seasons of physical domination when I could stay up all night and clean and clean and clean. I have also struggled with fatigue, injury, and chronic disease. Regardless of the season, I had no choice but to keep going... and I did. In this initial episode, we will deconstruct the habits of multiple peak performers from professional sports to learn from them. Then in the second episode, I also will share several keys to solo longevity that I have learned along the way from my triumphs and struggles.  I believe this will help all cleaning companies as we all have people cleaning, whether it is us or a team we've hired.Disclaimer: I am not a medical doctor. I am sharing what I've personally done for cleaning longevity. See your doctor before making any major changes to your routine. Baseline your level of health now and set goals on where you'd like to go. Use this podcast as a guide.Let's start with an analogy that takes me down vehicle memory lane. The joke in high school was that Ford stood for "fix or repair daily" and "fails on race day". My friends with Hondas boasted on their longevity and reliability. Hondas were the gold standard. My cars from age 16 to now have been in this order: Honda, Ford, Ford, Mitsubishi, Honda, Honda, Honda, Honda, Ford, Honda, Ford. Isn't that funny. I've owned 6 Hondas and 4 Fords. I won't go over every detail on our cars as that is probably boring. I will just say this. All of my cars have been great. I have so many memories from each. But I do generally agree after owning 4 Fords and 8 Hondas (my wife owned 2 Honda Odysseys) that the Hondas are way more reliable and spend less time in the shop. Sure there were some duds. We had an Odyssey that lasted 2 years and needed a new engine at 150,000 miles. We own a Ford Fiesta with 100,000 miles and a Honda Pilot with 140,000 miles and both are running great. But there is not doubt that our Hondas have been cheaper to operate and lasted a lot longer as 5 of the 8 were over 200,000 miles when we got rid of them.Read the rest of this article at the Smart Cleaning School website

Send us a textEuro tour pt 2! Talk about the difficult times in you career plus pointe shoe issues and UNHINGED stories. 

his week on The Baseline NBA Podcast, we're joined by ESPN NBA reporter Kendra Andrews for a power-packed episode you don't want to miss. Right as the news broke that the Denver Nuggets fired head coach Michael Malone, Kendra jumped on with us to give her immediate reaction and expert insight into what this means for the reigning champs and their future.But we didn't stop there. Kendra also weighed in on the state of the WNBA, previewing top prospects ahead of the 2025 WNBA Draft, and dropped some serious knowledge on how the league is evolving. We also asked the burning question: Is Paige Bueckers ready for the WNBA Spotlight? Kendra keeps it real and delivers must-hear perspective. Whether you're a hardcore NBA junkie or hyped for the next era of the WNBA, this episode delivers exclusive analysis, next-level insight, and that signature Baseline breakdown you love. Subscribe, Rate & Review – and don't forget to follow us on all platforms @NBABaseline for more unfiltered hoops talk every week!Become a supporter of this podcast: https://www.spreaker.com/podcast/the-baseline-nba-podcast--3677698/support.

N Engl J Med 2024;391:1673-1684Background: Non-ST elevation myocardial infarction (NSTEMI) is the most common acute coronary syndrome subtype in adults over 75 years old. However, these patients were underrepresented in landmark NSTEMI trials. Older adults with multiple comorbidities face an increased risk of mortality. While NSTEMI contributes to this risk, they also have competing risks such as advanced age, frailty, and chronic kidney disease. The presence of competing risks means that aggressively managing one condition may have a smaller impact on overall mortality compared to a younger, otherwise healthy adult with myocardial infarction, whose primary risk of death stems from the myocardial infarction itself. Additionally, comorbid conditions like advanced kidney disease and diffuse atherosclerosis can increase the risks associated with revascularization.Cardiology Trial's Substack is a reader-supported publication. To receive new posts and support our work, consider becoming a free or paid subscriber.A patient-level meta-analysis of smaller trials, including 1,479 patients, found that in elderly patients with NSTEMI, an invasive strategy reduced myocardial infarction and urgent revascularization but not mortality.The Older Patients with Non–ST-Segment Elevation Myocardial Infarction Randomized Interventional Treatment (SENRIOR-RITA) trial sought to assess invasive vs conservative management of elderly patients with NSTEMI, in a more pragmatic design.Patients: Eligible patients had to have type I NSTEMI and be 75 years or older.Patients were excluded if they had cardiogenic shock or life expectancy less than 1 year.Baseline characteristics: The trial randomized 1,518 patients from hospitals across England and Scotland – 753 randomized to invasive strategy and 765 to conservative strategy.The average age of patients was 82 years and 55% were men. Approximately 65% had hypertension, 31% had diabetes, 31% had hyperlipidemia, 31% had prior myocardial infarction, 15% had prior stroke or TIA, 21% had kidney disease, 15% had chronic obstructive pulmonary disease, and 5% were current smokers.The average Charlson comorbidity index was 5.Procedures: Patients were randomly assigned in a 1:1 ratio to undergo invasive or conservative strategy.In the invasive strategy, patients underwent coronary angiogram, and revascularization was performed as appropriate. In the conservative arm, patients were treated (unless contraindicated) with aspirin, a P2Y12 receptor antagonist, statin, beta-blocker and an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker. Patients in the conservative arm were allowed to have a coronary angiogram if they had worsening clinical status.Endpoints: The primary end point was a composite of cardiovascular death or nonfatal myocardial infarction. Secondary outcomes included all-cause death, subsequent coronary revascularization, hospitalization for heart failure, stroke and bleeding.Analysis was performed based on the intention-to-treat principle. The trial aimed to detect a hazard ratio of 0.78, assuming a 20% risk of the primary outcome in the conservative arm. A sample size of 1,668 patients with at least 688 primary outcome events would provide 90% power at 5% alpha, while 520 events would provide 80% power.Results: Among the patient randomized to the invasive arm, 90% underwent coronary angiography and 50% underwent revascularization. The medium number of days from admission to coronary angiography was 5. Among patients randomized to the conservative arm, 5.6% underwent coronary angiography within 7 days. The median follow-up time was 4.1 years.The primary outcome was not significantly different between both groups (25.6% with invasive vs 26.3% with conservative, HR: 0.94, 95%: 0.77 - 1.14; p= 0.53).There was also no difference in all-cause death (36.1% vs 32.3%), cardiovascular death (15.8% vs 14.2%), stroke (4.2% vs 5.2%), hospitalization for heart failure (10.9% vs 10.7%), or major bleeding (8.2% vs 6.4%) “incidence for invasive mentioned first”. Future coronary revascularization was more frequent in the conservative arm (13.7% vs 3.9%). Non-fatal myocardial infarction was significantly lower with an invasive strategy (11.7% vs 15.0%).Procedural related complications occurred in less than 1% of the patients.There were no significant subgroup interactions for the primary outcome.Conclusion: In older patients with NSTEMI, an invasive strategy compared to conservative strategy, did not reduce the primary composite endpoint of cardiovascular death or nonfatal myocardial infarction, over a median of 4.1 years.The trial enrolled fewer patients than planned, and the lower-than-expected event rate reduced its statistical power. Additionally, the median 5-day delay before coronary angiography may have biased the results toward the conservative strategy.Despite its limitations, this trial demonstrates that a conservative approach is a reasonable option for selected older patients with NSTEMI. It also highlights that, although enrolling older patients with comorbidities in trials is challenging, it is feasible, and greater effort is needed to include more of this population in future trials.Finally, in this trial of patients with myocardial infarction, about one-third died over a median of 4.1 years, with less than half of these deaths attributed to cardiovascular disease. Even if an invasive strategy had reduced cardiovascular mortality, its impact on all-cause mortality would have been less significant. This concept extends beyond this trial; when interventions are applied to older patients with multiple competing risks, their overall benefit diminishes.Cardiology Trial's Substack is a reader-supported publication. To receive new posts and support our work, consider becoming a free or paid subscriber. Get full access to Cardiology Trial's Substack at cardiologytrials.substack.com/subscribe

This week Kate, Gary, Mark and Henry discuss discontinuation of benzodiazepines and treatment of insomnia, the value of baseline cognitive testing of college athletes, vonoprazan vs PPI for preventing and treating ulcers, and whether herpes zoster vaccine reduces dementia risk.Show links:Essential Evidence Plus: www.essentialevidenceplus.comTapering benzos: https://pubmed.ncbi.nlm.nih.gov/39374004/ Baseline neuro eval for athletes: pubmed.ncbi.nlm.nih.gov/39741470/ David Kaufman, “We Need You in the Locker Room” https://thesagergroup.net/books/in-the-locker-room Vonoprazan vs PPIs for ulcers: https://pubmed.ncbi.nlm.nih.gov/39294424/ Zoster and dementia: https://pubmed.ncbi.nlm.nih.gov/40175543/ 

JAMA Intern Med 2023;183:407-415Background: As we have previously discussed, trials comparing invasive versus conservative management in patients with non-ST elevation myocardial infarction (NSTEMI) have yielded mixed results. The average age of participants in these studies was in the 60s, and multiple comorbidities were relatively uncommon. However, many NSTEMI patients seen in clinical practice are older and have multiple comorbidities. These patients have worse prognosis and have competing risks for mortality. Whether an invasive strategy provides a benefit for this population remains uncertain.Cardiology Trial's Substack is a reader-supported publication. To receive new posts and support our work, consider becoming a free or paid subscriber.The MOSCA-FRAIL trial sought to compare invasive vs conservative strategy in older adults with frailty and NSTEMI.Patients: Eligible patients had to have NSTEMI, be 70 years or older, and have frailty defined by 4 points or greater on the Clinical Frailty Scale.Patients were excluded if they were known to have nonrevascularizable coronary artery disease, significant concomitant non-ischemic heart disease, or life expectancy less than 12 months.Baseline characteristics: The trial randomized 167 patients from 13 hospitals in Spain – 84 randomized to invasive strategy and 83 to conservative strategy.The average age of patients was 86 years and 47% were men. Approximately 92% had hypertension, 56% had diabetes, 77% had hyperlipidemia, 31% had prior myocardial infarction, 27% had history of atrial fibrillation, 18% had prior stroke, 44% had chronic kidney disease, and 3% were current smokers.Procedures: Patients were randomly assigned in a 1:1 ratio to undergo invasive or conservative strategy.In the invasive strategy, patients underwent coronary angiogram within 72 hours of admission, and revascularization was performed as appropriate. In the conservative arm, patients were treated with medical therapy alone. A coronary angiogram was permitted for recurrent ischemia during the index admission.Medical treatment was given according to the guidelines at the time. In both arms, dual antiplatelet was recommended for one year. In patients with high bleeding risk or taking an oral anticoagulant, one antiplatelet could be stopped after the first month.Endpoints: The primary end point was the number of days alive and out of the hospital between discharge from the index hospitalization to 1 year. The coprimary end point was the composite of cardiac death, reinfarction, or post-discharge revascularization.Analysis was performed based on the intention-to-treat principle. The estimated sample size to provide 80% power at 5% alpha was 176 patients. This assumed that the number of days for the primary outcome in the conservative arm was 273 days and that an invasive strategy would increase that by 20%, that is 55 days.Results: Due to the COVID pandemic, the trial was terminated early after randomizing 95% of the planned sample size. During the index admission, 98% of the patients in the invasive arm underwent coronary angiogram and 60% underwent revascularization. Among patients in the conservative arm, 9.6% underwent revascularization due to recurrent ischemia during the index admission.The primary outcome (number of days alive and out of the hospital between discharge from the index hospitalization to 1 year) was numerically lower with the invasive arm but this was not statistically significant (mean difference 28 days, 95% CI: -7 – 62; p= 0.12).There was no difference in the coprimary end point - cardiac death, reinfarction, or post-discharge revascularization – absolute values were not provided. The invasive strategy was associated with significantly more bleeding events requiring hospitalization (8 patients vs 1 patient, incidence rate ratio: 14.9, 95% CI: 1.7 – 129.0; p= 0.02) including 4 deaths related to bleeding.Conclusion: In older, frail patients with NSTEMI, an invasive strategy did not significantly reduce the number of days of being alive and out of the hospital at 1-year. It also did not reduce the coprimary end point which was the composite of cardiac death, reinfarction, or post-discharge revascularization. An invasive strategy was associated with more bleeding requiring hospitalization.The trial is small, and its results should be interpreted with caution. Nonetheless, it is an important study that paves the way for future, larger trials in this population. The primary endpoint is both meaningful and relevant to this population. The average age of participants in this trial is approximately 20 years older than those in TACTICS-TIMI 18, RITA 3, and ICTUS. It is important to recognize that older, frail patients with multiple comorbidities are significantly underrepresented in clinical trials and likely derive less benefit or even harm from interventions.Cardiology Trial's Substack is a reader-supported publication. To receive new posts and support our work, consider becoming a free or paid subscriber. Get full access to Cardiology Trial's Substack at cardiologytrials.substack.com/subscribe

Jon Heyman: Baseline number to sign Kyle Tucker is at least $500 million full 1046 Mon, 07 Apr 2025 14:45:46 +0000 EVnzvMeKD0JfZNMS6RJeGiOEJ6vqrumQ mlb,chicago cubs,sports Mully & Haugh Show mlb,chicago cubs,sports Jon Heyman: Baseline number to sign Kyle Tucker is at least $500 million Mike Mulligan and David Haugh lead you into your work day by discussing the biggest sports storylines in Chicago and beyond. Along with breaking down the latest on the Bears, Blackhawks, Bulls, Cubs and White Sox, Mully & Haugh routinely interview the top beat writers in the city as well as team executives, coaches and players. Recurring guests include Bears receiver DJ Moore, Tribune reporter Brad Biggs, former Bears coach Dave Wannstedt, Pro Football Talk founder Mike Florio, Cubs president of baseball operations Jed Hoyer and Cubs pitching coach Tommy Hottovy.Catch the Mully & Haugh Show live Monday through Friday (5 a.m.- 10 a.m. CT) on 670 The Score, the exclusive audio home of the Cubs and the Bulls, or on the Audacy app. For more, follow the show on X @mullyhaugh. 2024 © 2021 Audacy, Inc. Sports False https://player.amper

EP190: Orange Monday, Flu Vaccine Study, Hochul vs Feds Over Medicaid, Masters WeekSPORTSMasters Week https://golf.com/lifestyle/2025-masters-picks-win-staff-betting-augusta/CLICKSBitcoin/GameStop - https://decrypt.co/312732/gamestop-1-5-billion-offering-bitcoin-reserveFlu Vaccine https://www.trialsitenews.com/a/landmark-cleveland-clinic-study-finds-flu-vaccine-ineffectiveand-possibly-harmfulfor-working-adults-in-2024-2025-season-84b3b608POLITICSNew York State https://nypost.com/2025/04/06/opinion/new-york-is-plotting-another-tax-hike-to-keep-feeding-health-care-special-interests/Bill Hammond https://nypost.com/2025/03/07/opinion/kathy-hochul-cries-wolf-over-medicaid-cuts-to-hide-her-political-abuse-of-its-funds/Empire Center https://www.empirecenter.org/publications/health-workforce-jumps-by-another-10-percent/Orange Monday https://finance.yahoo.com/news/live/trump-tariffs-live-updates-trump-digs-in-says-markets-may-have-to-take-medicine-as-stocks-plunge-191201144.htmlLiberation Day!Trump announces reciprocal tariffsSummary of the top three points of the announcement:Baseline 10% tariffs on all imported goods to the United States.Reciprocal tariffs targeting approximately 60 countries deemed “worst offenders,” with rates ranging from 20% to 50%. Notable examples include 34% on Chinese goods and 20% on EU imports.A 25% tariff on foreign-made vehicles and the closure of duty-free loopholes for Chinese goods under $800.##  About the Sports, Clicks & Politics PodcastSCAPP is a weekly podcast with a Livestream every Monday at 12pm on eastern.  Join hosts Shawn Hannon and Ben Hussong as they separate the latest news from the noise impacting New York State. The podcast has frequent guest interviews for additional perspectives in the worlds or sports, politics and beyond!Follow the show on social mediaWebsite: scappodcast.comFacebook: facebook.com/scappodcastTwitter: @SCAPPodcastFollow Shawn & Ben on social mediaFacebook: facebook.com/hannon44 Twitter: @hannon44Facebook: facebook.com/ben.hussong.3Twitter: @benhussong 

ROMANTICIZE ... mehr als nur ein schicker Trend. Vielleicht öffnet dir die Romantisierung des Augenblicks das Tor zu einer ganz neuen schöpferischen Kraft. Vor einiger Zeit sagte meine Mentorin zu mir: THE LIFE YOU LIVE DIDNT HAPPEN BY ACCIDENT. Und ich verstand, dass sie recht hatte, dass ich es aber immer und immer wieder genauso behandelte. So, als sei es zufällig passiert, als wäre es normal, als wäre es eigentlich schon gar nicht mehr das, wofür ich hier auf dieser Erde bin. Also habe ich gelernt, zu romantisieren. Klar habe ich hohe Standards, und je besonderer mein Alltag wird, je höher werden meine Standards. So dass mein JETZT die Baseline an akzeptierter Normalität war. Bis ich gelernt habe, dass die Liebe zum Jetzt und die Vorfreude auf das DANN sich sehr gut miteinander verstehen. Vielleicht kannst auch du deinen Alltag durch Romantisierung noch ein bisschen exklusiver machen während du dich auf die weiteren Exzellenten Erfahrungen freust die du erschaffst. Folge direkt herunterladen

Dean and John Cordero from the Kitchen Store talks trends such as lighting and the baseline drawers. Dean talks about the blind corner problem in many kitchens and other tricky problems.  Dean and John dive into the idea of customization as luxury. Lastly, Dean talks wood material when it comes to cabinets: oak, maple, cherry, walnut

TGIF, with the NFL Draft being less than three weeks away, we start to filter, decipher and assess the state of the division as it pertains to the 2025 draft. We'll use the latest 1st rd mock from NFL Analyst Lane Zierline and discuss the picks he's projected to the AFC North teams. Then, of course we'll throw our hands up at those projections and tell you how it's really going down. Tap-in with the “Homies” Tate, Big-G, Pay & B-Dirt on YouTube or wherever you listen to your audio podcasts.  Learn more about your ad choices. Visit megaphone.fm/adchoices

Baseline ten percent import taxes are now in effect on all goods coming into the U.S., Mayor Wu makes a big announcement, and a week of jury selection in the Karen Read re-trial is now in the books. Stay in "The Loop" with #iHeartRadio.

In this week's episode, Josh and I are discussing the new tool hitters are using this season in Major League Baseball. And no, they are not cheating. It is within the rule book. What are your thoughts? Then of course we give you our take on the Final Four and the National Championship.

Hour 2 Audio from WGIG-AM and FM in Brunswick, GA

Draper, Eala, Mensik, Andreeva...We have some new faces in the winners circle.  Indian Wells and Maimi Open did not disapoint. We give a run down of all our favorite moments from the last 3 weeks on tour. Enjoy

The Rich Zeoli Show- Hour 3: 5:05pm- In response to President Donald Trump's tariff announcement, futures on the S&P 500 are initially down just over 1%. Notably, Canada and Mexico—two of the United States' top trading partners—were not explicitly mentioned for new tariffs. 5:15pm- Will the Trump Administration remove tariffs on countries that remove tariffs on American-made goods? Trump stated: “To all foreign presidents, prime ministers, kings, queens, ambassadors, and everyone else who will soon be calling to ask for exemptions to these tariffs, I say—terminate your own tariffs, drop your barriers, don't manipulate your currencies…and start buying tens of billions of dollars of American goods.” 5:20pm- Listeners call into the show and react to President Donald Trump's executive order establishing new tariffs on foreign nations. Will this move negatively impact the U.S. economy? Or will it result in other countries removing their tariffs on American-made goods—resulting in truly free trade. 5:30pm- Israel currently places a 33% tariff on imported American products. However, in anticipation of President Donald Trump's “Liberation Day” announcement, Israeli Finance Minister Bezalel Smotrich signed a plan to eliminate tariffs on all American imports. Trump's tariff on Israeli products would be 17%. Weekday afternoons on Talk Radio 1210 WPHT, Rich Zeoli gives the expert analysis and humorous take that we need in this crazy political climate. Along with Executive Producer Matt DeSantis and Justin Otero, the Zeoli show is the next generation of talk radio and you can be a part of it weekday afternoons 3-7pm.

Keywords: Jeep Talk Show, Round Table, Hot or Not Jeep mods, beadlocks vs all-terrains, lift vs lockers, soft top vs hard top, manual vs automatic, rock lights debate, Easter Jeep Safari 2025, Tyree Lights, YJL at EJS, Hot Springs Jeep event, Jeep community podcast Description: Join Tony and the Jeep Talk Show crew for a lively Round Table episode as we dive into a “Hot or Not” debate inspired by Chick Chat's Natalie and Janet!

N Engl J Med 2005;353:1095-1104Background: Prior trials on revascularization in patients with acute coronary syndromes without ST-segment elevation have yielded mixed results. While FRISC II and TACTICS-TIMI 18 demonstrated a significant reduction in myocardial infarction, this benefit was not observed in RITA 3. None of these trials showed a significant reduction in mortality. Further research is needed to guide treatment strategies in this population, particularly after the introduction of early use of clopidogrel and intensive lipid-lowering therapy.Cardiology Trial's Substack is a reader-supported publication. To receive new posts and support our work, consider becoming a free or paid subscriber.The Invasive versus Conservative Treatment in Unstable Coronary Syndromes (ICTUS) trial sough to test the hypothesis that an early invasive strategy is superior to selective invasive strategy for patients with non-ST elevation myocardial infarction (NSTEMI).Patients: Eligible patients had to have all of the following: Worsening symptoms of ischemia or symptoms at rest with the last episode being 24 hours before randomization, elevated cardiac troponin T level (≥0.03 μg per liter); and either ischemic EKG changes (defined as ST-segment depression or transient ST-segment elevation exceeding 0.05 mV, or T-wave inversion of ≥0.2 mV in two contiguous leads) or a documented history of coronary artery disease.Patients were excluded if they were older than 80 years, had an indication for primary percutaneous coronary intervention or fibrinolytic therapy, hemodynamic instability or overt congestive heart failure, oral anticoagulant drugs use in the past 7 days, fibrinolytic treatment within the past 96 hours, percutaneous coronary intervention within the past 14 days, elevated bleeding risk, plus others.Baseline characteristics: The trial randomized 1,200 patients from 42 Dutch hospitals – 604 randomized to early invasive strategy and 596 randomized to selective invasive strategy.The average age of patients was 62 years and 74% were men. Approximately 39% had hypertension, 14% had diabetes, 35% had hyperlipidemia, 23% had prior myocardial infarction and 41% were current smokers.Approximately 48% of the patients had ST deviation equal to or greater than 0.1 mV.Procedures: Patients were randomly assigned in a 1:1 ratio to undergo early invasive vs selective invasive strategy.Patients received 300 mg of aspirin at the time of randomization, followed by at least 75 mg daily indefinitely, and enoxaparin (1 mg/kg for a maximum of 80 mg) subcutaneously twice daily for at least 48 hours. The early use of clopidogrel (300 mg immediately, followed by 75 mg daily) in addition to aspirin was recommended to the investigators after the drug was approved for acute coronary syndrome in 2002. Intensive lipid-lowering therapy, preferably atorvastatin 80 mg daily or the equivalent was recommended as soon as possible after randomization. All interventional procedures during the index admission were performed with the use of abciximab.Patients assigned to the early invasive strategy were scheduled to undergo angiography within 24 - 48 hours after randomization. Patients assigned to the selective invasive strategy underwent coronary angiography if they had refractory angina despite optimal medical therapy, hemodynamic or rhythm instability, or significant ischemia on pre-discharge exercise test.In both groups, percutaneous coronary intervention (PCI) was performed when appropriate, without providing more details in the manuscript.The level of creatine kinase MB was measured at 6-hour intervals during the first day, after each new clinical episode of ischemia, and after each percutaneous revascularization procedure.Endpoints: The primary endpoint was a composite of all-cause death, myocardial infarction, or rehospitalization for angina at 1-year.The estimated sample size to provide 80% power to detect 25% relative risk difference between the two treatment groups at 5% alpha was 1,200 patients. This assumed that 21% of the patients in the early invasive arm would experience the primary outcome.Results: During the index admission, 98% of the patients in the early invasive strategy arm underwent coronary angiogram compared to 53% in the selective invasive arm. At 1-year, 79% of the patients in the early invasive strategy arm underwent revascularization compared to 54% in the selective invasive arm.The primary outcome was not significantly different between both treatment groups (22.7% with early invasive vs 21.2% with selective invasive, RR: 1.07; 95% CI: 0.87 - 1.33; p= 0.33). All-cause death was the same in both groups (2.5%). Myocardial infarction was significantly higher with the early invasive strategy (15.0% vs. 10.0%, RR: 1.50, 95% CI: 1.10 – 2.04; p= 0.005), while rehospitalization for angina was lower with early invasive (7.4% vs. 10.9%, RR: 0.68, 95% CI: 0.47 – 0.98; p= 0.04). Most myocardial infarctions were revascularization related and these were significantly more frequent with early invasive (11.3% vs 5.4%). Spontaneous myocardial infarctions were 3.7% with early invasive and 4.6% with selective invasive and this was not statistically significant.Major bleeding, not related CABG, during the index admission was more frequent with the early invasive strategy (3.1% vs 1.7%).There were no significant subgroup interactions for the primary outcome, including based on ST deviation and troponin levels.Conclusion: In patients with NSTEMI, an early invasive strategy was not superior to selective invasive strategy in reducing the composite endpoint of all-cause death, myocardial infarction, or rehospitalization for angina at 1-year. An early invasive strategy was associated with more myocardial infarctions with a number needed to harm of 20 patients, which was secondary to revascularization related myocardial infarction. An early invasive strategy reduced rehospitalization for angina with a number needed to treat of approximately 29 patients.The ICTUS trial showed that revascularization can cause harm and highlighted how counting procedural myocardial infarctions can influence outcome estimates. While there is ongoing debate about the significance of periprocedural myocardial infarctions, evidence indicates an association with increased mortality. Whether periprocedural myocardial infarctions are 'less severe' than spontaneous myocardial infarctions remains controversial, as their impact varies based on infarct size and patient characteristics. This underscores the importance of including all-cause mortality or advanced systolic heart failure as endpoints in trials of revascularization.Patients in ICTUS received better background medical therapy compared to prior trials in this area. While this could be responsible for the divergent results compared to other prior trials. It also highlights the heterogeneity of NSTEMI patients and that an invasive strategy is not appropriate for all.Cardiology Trial's Substack is a reader-supported publication. To receive new posts and support our work, consider becoming a free or paid subscriber. Get full access to Cardiology Trial's Substack at cardiologytrials.substack.com/subscribe

Join us as Dr. Matthew Paletta discusses the importance of regular health checkups and screenings for young adults. Establishing a baseline of care in your 20s and 30s can make a big difference in the future. Find out how early detection of health issues, preventive care, and managing long-term conditions can keep you healthy and why mental health is key to overall wellness. Do you want to know more?Check out the Providence blog for more information on this and other health related topics. To learn more about our mission programs and services, go to Providence.org.Follow us on social media to get continued information on other important health care topics. You can  connect with us on LinkedIn, Facebook, TikTok, Instagram and X.For all your healthcare information on the go, download the Providence app. Whether you're tracking symptoms, scheduling appointments, or connecting with your healthcare providers, the Providence app has your back.To learn more about the app, check out the Wellness Brief podcast episode. Wellness Brief: Simplifying Care-There's an App for That. We'd love to hear from you. You can contact us at FutureOfHealthPodcasts@providence.org

In this week's episode, Josh and I are discussing the changes to our mock drafts. We discuss how free agency and trades have affected our projections. Then of course we discuss the madness that is March Madness. We talk about how rare it is to see very little upsets. It is wild!

Emily Allen transformed her relationship with alcohol while raising her children, and now guides women in creating an exciting next chapter filled with clarity, authentic connections, and true freedom as they transition to their empty nest years.• Daily wine had become a numbing ritual, especially during COVID lockdowns• A horrible Christmas morning hangover became the turning point• Dry January 2021 became the gateway to permanent sobriety• Sleep quality dramatically improved within weeks of quitting• "Wine mom culture" normalizes drinking as necessary for stress management• Moderation attempts create mental gymnastics and decision fatigue• Social relationships often shift, revealing which connections were alcohol-dependent• Breaking neural pathways requires creating new evening rituals• Midlife health risks from alcohol increase significantly, especially breast cancer risk• Baseline anxiety levels noticeably decrease after sustained sobriety• Empty nesting provides the perfect opportunity for transformation• Emily now offers a 12-week group program launching May 12thVisit livingfreewithemily.com to join the waitlist for Emily's 12-week group program or take her free "alcohol-free personality" quiz.I would love to hear from you! What did you think of the episode? Share it with me :) Let's Be FriendsHang out with Heather on IG @greenpalettekitchen or on FB HERE.Let's Talk!Whether you are looking for 1-1 nutrition coaching or kitchen coaching let's have a chat. Click HERE to reach out to Heather.Did You Love This Episode? "I love Heather and the Real Food Stories Podcast!" If this is you, please do not hesitate to leave a five-star review on Apple or wherever you listen to podcasts.

The Lancet 2002;360:743-751Background: The TACTICS-TIMI 18 trial showed that an early invasive strategy in beneficial in selected patients with unstable angina or non-ST-elevation myocardial infarction (NSTEMI). These positive findings contrasted the findings from some earlier studies.Cardiology Trial's Substack is a reader-supported publication. To receive new posts and support our work, consider becoming a free or paid subscriber.The British Heart Foundation RITA 3 randomized trial sought to compare invasive vs conservative strategy in patients with unstable angina or NSTEMI, similar to the trial question of TACTICS-TIMI 18.Patients: Eligible patients had suspected cardiac chest pain at rest with at least one of the following: Evidence of ischemia on electrocardiogram (ST depression, transient ST elevation, old left bundle branch block, or T wave inversion), pathologic Q waves suggesting previous myocardial infarction, or documented coronary artery disease on prior coronary angiogram.Patients were excluded if they had evolving myocardial infarction in which reperfusion therapy was indicated. Patients were also excluded if creatine kinase or creatine kinase MB concentrations were twice the upper limit of normal before randomization, if they had myocardial infarction within a month, had percutaneous coronary intervention (PCI) in the previous 12 months, or coronary artery bypass grafting (CABG) at any time.Baseline characteristics: The trial randomized 1,810 patients – 895 randomized to the invasive strategy and 915 randomized to conservative strategy. Patients were recruited from 45 hospitals in England and Scotland.The average age of patients was 63 years and 62% were men. Approximately 35% had hypertension on drugs, 13% had diabetes and 28% had prior myocardial infarction.The majority (92%) of the patients were enrolled because they met the criteria for evidence of ischemia on electrocardiogram.Procedures: Patients were randomly assigned in a 1:1 ratio to undergo invasive vs conservative strategy.In the conservative arm, patients received aspirin and enoxaparin 1mg/kg subcutaneously twice a day for 2-8 days. Beta-blockers, other antiplatelets and glycoprotein IIb/IIIa inhibitors could also be used. Coronary angiography could be performed if patients had anginal symptoms at rest or with minimal exertion despite appropriate therapy or if they had ischemia on stress testing.Patients in the invasive strategy arm received similar medical therapy to the conservative arm. Coronary angiogram was to be performed as soon as possible after randomization and ideally within 72 hours. Revascularization was recommended for lesions of at least 70% stenosis or 50% or more if left main.Endpoints: The trial had two co-primary outcomes. The first was a composite of death from any cause, nonfatal myocardial infarction, or refractory angina at 4 months. The second was a composite of death from any cause or nonfatal myocardial infarction at 1 year.Analysis was performed based on the intention-to-treat principle. The estimated sample size to provide 80% power at 5% alpha, was 1,770 patients. This assumed that 12% of the patients in the conservative arm would experience the outcome of death or non-fatal myocardial infarction at 1-year, and that the invasive strategy would result in 33% relative risk reduction in this outcome.Results: In the invasive strategy, 97% of the patients underwent coronary angiogram at a median of 2 days after randomization, and 55.3% underwent PCI or CABG. In the conservative arm, 10.3% had revascularization during the index admission, and 17.3% had revascularization at 1-year. The median follow time was 2 years and 97% of the patients had at least 1-year of follow up.The first primary composite outcome of death from any cause, nonfatal myocardial infarction, or refractory angina at 4 months was lower with the invasive strategy (9.6% vs 14.5%, HR: 0.66, 95% CI: 0.51 – 0.85; p= 0.001). The second primary composite outcome of death from any cause or nonfatal myocardial infarction at 1 year was not significantly different between both groups (7.6% with invasive vs 8.3% with conservative, HR: 0.91, 95% CI: 0.67 – 1.25; p= 0.58). At 1-year, 4.6% patients died in the invasive arm compared to 3.9% in the conservative arm, and this was not statistically significant. Myocardial infarction at 1-year occurred in 3.8% of the patients in the invasive arm compared to 4.8% in the conservative arm, and this was not statistically significant as well.All bleeding occurred in 8.2% in the invasive arm and 3.5% in the conservative arm.Subgroup analysis showed that men benefited from an invasive strategy while women did not (p for interaction= 0.011). The endpoint of death or myocardial infarction at 1-year, in women, was 5.1% in the conservative arm and 8.6% in the invasive arm, while in men, the incidence of this endpoint was 10.1% in the conservative arm and 7.0% in the invasive arm.Conclusion: In patients with unstable angina or NSTEMI, an invasive strategy compared to conservative strategy, reduced refractory angina but not myocardial infarction or death at 1-year.The reduction in angina is a subjective endpoint, prone to bias and faith healing, as we have previously discussed in other trials of PCI. The reduction in this endpoint alone should not justify widespread adoption of invasive strategy for unstable angina or NSTEMI.A key distinction between this trial and TACTICS-TIMI 18—which demonstrated a reduction in myocardial infarction with an invasive approach—is that this study included patients with smaller myocardial infarctions. Only 41% of participants had ST depression or transient ST elevation, and patients were excluded if creatine kinase or creatine kinase MB levels were more than twice the upper limit of normal before randomization. This highlights the heterogeneity among patients with unstable angina and NSTEMI, where baseline risk and the extent of myocardial necrosis influence treatment effects. We encourage you to read again the subgroup interactions of TACTICS-TIMI 18.Additionally, in the current era, high-sensitivity troponin assays enable the detection of smaller myocardial infarctions, potentially limiting the applicability of older trial results to all present NSTEMI patients.Cardiology Trial's Substack is a reader-supported publication. To receive new posts and support our work, consider becoming a free or paid subscriber. Get full access to Cardiology Trial's Substack at cardiologytrials.substack.com/subscribe

In today's episode, host Pete Moore is joined by dynamic entrepreneur, Kevin Wathey. Kevin shares his journey from a deeply personal tragedy with his Mom, to becoming a multi-faceted entrepreneur, spearheading innovative projects across the globe. The discussion dives into two latest (and very complementary) ventures, including a new wellness resort set in Costa Rica, tailored for high-performing individuals seeking holistic health transformations.  Kevin also touches on Baseline, his health tech platform designed to revolutionize personal health management by offering customized experiences based on unique biological data. With insights on personal motivation, the importance of wellness, and his ambitious plans for future locations in Italy and South Africa, this episode is a must-listen for those interested in the fusion of hospitality, technology, and health. On building out Velara, Kevin mentions, "The acquisition in Costa Rica was a preexisting boutique hotel. It was 24 rooms, two restaurants, a spa, and five acres of beachfront, on the Pacific Coast in the in the Nicoya Blue Zone. The intention was never to keep it as is, but to expand it. Right before we closed on it, the previous owner came to me and said, 'Hey. We have two extra plots of land adjacent. Would you like those as well?" Key themes discussed Overcoming Limits Through Determination Opens Yoga Studio at 24 Beachfront Hotel Expansion Project Pura Vida: A Subtractive Approach Baseline: Life Quality Scoring Platform Redefining Success and Profitability Embrace Workout Recovery Now A few key takeaways:  1. Tragic Inspiration: Kevin shared a deeply personal story about how his mother's battle and subsequent passing from pancreatic cancer inspired him to pursue a "life without limitations." This taught him that whatever we focus on, we have the potential to accomplish. 2. Career Path: Kevin's journey from playing semi-pro hockey to getting into acting, then discovering yoga in Bali, and eventually moving into the hospitality industry, showcases his wide variety of experiences. These varied paths have shaped his entrepreneurial ventures today. 3. Building in Costa Rica: Kevin discussed acquiring and expanding a pre-existing boutique hotel in Costa Rica into a larger resort with a focus on health and wellness tailored to guests through testing prior to their stay. This venture targets high-performing individuals seeking more holistic health experiences. 4. Baseline Health Tech Platform: Complementing the resort, Kevin is also developing Baseline, a health tech platform that provides personalized health scores based on lifestyle and behavioral interventions. It's designed to track a client's health progress over time and is aimed at reducing dependence on pharmaceuticals. 5. Entrepreneurial Vision: Kevin is balancing two major projects simultaneously, driven by an overarching vision of holistic wellness and lifestyle improvement. He sees both as complementary, each aiding the success of the other. Click here to download transcript.   Resources:  Kevin Wathey: https://www.linkedin.com/in/kevinwathey  Baseline: https://www.getbaseline.com  Velara Resorts: https://velararesorts.com Prospect Wizard: http://www.theprospectwizard.com Promotion Vault: http://www.promotionvault.com HigherDose: http://www.higherdose.com

Watch here for a video interview with JACC Associate Editor Michelle Kittleson, MD, FACC, and author Mathew S. Muarer, MD, FACC, as they discuss Dr. Maurer's study published in JACC and presented at ACC.25. This exploratory analysis of HELIOS-B assessed the efficacy of vutrisiran versus placebo in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) by subgroups of baseline heart failure severity (primarily by NYHA class and NT-proBNP levels). Vutrisiran showed evidence of benefit vs placebo on mortality, cardiovascular events, functional capacity, quality of life, and cardiac biomarkers across the range of baseline disease severities in patients enrolled in HELIOS-B, with greatest benefit observed in patients with earlier, less severe disease.

Was Draymond's 'soft' accusation against KAT fact or fiction? We dissect the fiery exchange that ignited the internet! Plus, the Kings' season hits a wall as Fox is sidelined – are the Spurs now officially tanking? Memphis honors the 'Grindfather' Tony Allen, joining Zach and Marc in the rafters! Steve Kerr cements his legacy as Golden State's all-time winningest coach, and Steph 'Effortless' Curry hits an unbelievable 4,000 career threes! But can he reach 5K?With playoff hopes hanging in the balance, whose return will be the ultimate game-changer? LeBron's Lakers? Kuminga's Warriors? Porzingis' Celtics? Randle/Gobert for the Wolves? Powell's Clippers? Trae's Hawks? Amen's Rockets? Ivey's Pistons? Or will Brunson's return propel the Knicks? We breakdown the crucial comebacks that could reshape the entire postseason landscape.Don't miss this explosive episode!The second half of the basketball season is here, and the race to the playoffs is heating up on PrizePicks, THE BEST place to cash in on your favorite sports. Don't miss your chance to cash-in as the league's best fight for playoff positioning takes place..Sign up today and get $50 instantly when you play $5! You don't even need to win to receive the $50 bonus, it's guaranteed when you use the promo code CLNS. PrizePicks also offers weekly promotions that can lead to big payouts and is available in more than 30 states, including California, Texas, Georgia and Florida.PrizePicks is truly the best way to win real money with all the various opportunities to play and collect your winnings. Due to the enormous selection of players and stat types available, we can mix and match our playing strategies based on personal preferences.I might take Jayston Tatum for more than 27 points and Jrue Holiday for more than 2 steals to mix in some defense in my selections. Do you think Steph Curry will get More than 5 3-pointers next week? Giannis for More than 35 points? Cook up hot takes with your friends and win real money this basketball season when you and your crew Run Your Game on PrizePicks.And for those who love a quick win, PrizePicks is the way to go. You can make your picks and submit your entry in less than 60 seconds! So, what are you waiting for? “Download the app today and use code CLNS to get $50 instantly after you play your first $5 lineup!”Remember, with PrizePicks, it's as simple as picking more or picking less. Again that's promo code CLNS to get $50 after you play your first $5 lineup. The Baseline is rocking with Prize Picks and you should too. “PrizePicks. Run Your Game!”Become a supporter of this podcast: https://www.spreaker.com/podcast/the-baseline-nba-podcast--3677698/support.

In this week's episode, Josh and I are continuing our favorite tradition of completing our brackets with you all! We breakdown every single matchup. We talk about some upsets we see, plus I talk about how North Carolina should have never been in the tournament.

In this episode of Grounded: The regenerative farming podcast, Kyle and Stuart talk to award-winning nutritionist and gut health expert Dr Lucy Williamson. Lucy originally worked as a mixed practice vet for 15 years before retraining as a nutritionist, fascinated by the link between healthy soil, our food and gut health.  She is a huge advocate for regenerative farming and offers courses explaining the importance of regen systems to the public, as well as advice on what to eat to support gut health. Lucy also works with farms and food businesses to support them in promoting their nutritional and environmental messaging.You can find out more by going to Lucy's website at www.lwnutrition.co.ukThis podcast is brought to you by Regenerate Outcomes.Regenerate Outcomes supports farmers to grow profits and improve crop and livestock performance by building functional soil.Receive one-on-one mentoring from experienced regenerative farmers to increase the productivity of your soil, cut costs and reduce external inputs.Baseline and measure changes in soil carbon to generate verified carbon credits which you can retain or sell for additional income. No cost to join. No cost to leave.For more information go to www.regenerateoutcomes.co.uk

Dans cet épisode, Emmanuel et Arnaud discutent des dernières nouvelles du dev, en mettant l'accent sur Java, l'intelligence artificielle, et les nouvelles fonctionnalités des versions JDK 24 et 25. Ils abordent également des sujets comme Quarkus, l'accessibilité des sites web, et l'impact de l'IA sur le trafic web. Cette conversation aborde les approches pour les devs en matière d'intelligence artificielle et de développement logiciel. On y discute notamment des défis et des bénéfices de l'utilisation de l'IA. Enfin, ils partagent leurs réflexions sur l'importance des conférences pour le développement professionnel. Enregistré le 14 mars 2025 Téléchargement de l'épisode LesCastCodeurs-Episode-323.mp3 ou en vidéo sur YouTube. News Langages Java Metal https://www.youtube.com/watch?v=yup8gIXxWDU Peut-être qu'on la déjà partagé ? Article d'opinion Java coming for AI https://thenewstack.io/2025-is-the-last-year-of-python-dominance-in-ai-java-comin/ 2025 pourrait être la dernière année où Python domine l'IA. Java devient un concurrent sérieux dans le domaine. En 2024, Python était toujours en tête, Java restait fort en entreprise, et Rust gagnait en popularité. Java est de plus en plus utilisé pour l'AI remettant en cause la suprématie de Python. article vient de javaistes la domination de python est cluturelle et plus technique (enfin pour les ML lib c'est encore technique) projets paname et babylon changent la donne JavaML est populaire L'almanach java sur les versions https://javaalmanac.io/ montre kes APIs et les diff entre versions puis les notes ou la spec java Les nouvelles de JDK 24 et du futur 25 https://www.infoq.com/news/2025/02/java-24-so-far/?utm_campaign=infoq_content&utm_source=infoq&utm_medium=feed&utm_term=global JDK 24 a atteint sa première phase de release candidate et sera officiellement publié le 18 mars 2025. 24 nouvelles fonctionnalités (JEPs) réparties en 5 catégories : Core Java Library (7), Java Language Specification (4), Security Library (4), HotSpot (8) et Java Tools (1). Project Amber : JEP 495 “Simple Source Files and Instance Main Methods” en quatrième preview, visant à simplifier l'écriture des premiers programmes Java pour les débutants. Project Loom : JEP 487 “Scoped Values” en quatrième preview, permettant le partage de données immuables entre threads, particulièrement utile avec les virtual threads. Project Panama : JEP 489 “Vector API” en neuvième incubation, continuera d'incuber jusqu'à ce que les fonctionnalités nécessaires de Project Valhalla soient disponibles. Project Leyden : JEP 483 “Ahead-of-Time Class Loading & Linking” pour améliorer le temps de démarrage en rendant les classes d'une application instantanément disponibles au démarrage de la JVM. Sécurité quantique : Deux JEPs (496 et 497) introduisant des algorithmes résistants aux ordinateurs quantiques pour la cryptographie, basés sur les réseaux modulaires. Sécurité renforcée : JEP 486 propose de désactiver définitivement le Security Manager, tandis que JEP 478 introduit une API de dérivation de clés. Optimisations HotSpot : JEP 450 “Compact Object Headers” (expérimental) pour réduire la taille des en-têtes d'objets de 96-128 bits à 64 bits sur les architectures 64 bits. (a ne aps utiliser en prod!) Améliorations GC : JEP 404 “Generational Shenandoah” (expérimental) introduit un mode générationnel pour le Garbage Collector Shenandoah, tout en gardant le non generationel. Évolution des ports : Windows 32-bit x86 ca sent le sapin JEP 502 dans JDK 25 : Introduction des “Stable Values” (preview), anciennement “Computed Constants”, offrant les avantages des champs final avec plus de flexibilité pour l'initialisation. Points Supplémentaires sur JDK 25 Date de sortie : JDK 25 est prévu pour septembre 2025 et représentera la prochaine version LTS (Long-Term Support) après JDK 21. Finalisation de l'on-ramp : Gavin Bierman a annoncé son intention de finaliser la fonction “Simple Source Files” dans JDK 25, après quatre previews successives. CDS Object Streaming : Le JEP Draft 8326035 propose d'ajouter un mécanisme d'archivage d'objets pour Class-Data Sharing (CDS) dans ZGC, avec un format d'archivage et un chargeur unifiés. HTTP/3 supporté dans HttpClient Un article sur l'approche de Go pour éviter les attaques par chemin de fichier https://go.dev/blog/osroot Librairies Quarkus 3.19 es sorti https://quarkus.io/blog/quarkus-3-19-1-released/ UBI 9 par defaut pour les containers En plus de AppCDS, support tu cache AOT (JEP 483) pour demarrer encore plus rapidement Preuve de possession dans OAuth tokers 2 Mario Fusco sur les patterns d'agents en Quarkus https://quarkus.io/blog/agentic-ai-with-quarkus/ et https://quarkus.io/blog/agentic-ai-with-quarkus-p2/ premier article sur les patterns de workflow chainer, paralleliser ou router avec des exemples de code qui tournent les agents a proprement parler (le LLM qui decide du workflow) les agents ont des toolbox que le LLM peut decided d'invoquer Le code va dans les details et permet de mettre les interactions en lumiere tracing rend les choses visuelles Web Le European Accessibility Act (EAA) https://martijnhols.nl/blog/the-european-accessibility-act-for-websites-and-apps Loi européenne sur l'accessibilité (EAA) adoptée en 2019 Vise à rendre sites web et apps accessibles aux personnes handicapées Suivre les normes WCAG 2.1 AA (clarté, utilisabilité, compatibilité) Entreprises concernées : banques, e-commerce, transports, etc. Date limite de mise en conformité : 28 juin 2025 2025 c'est pour les nouveaux developpements 2027 c'est pour les applications existantes. bon et je fais comment pour savoir si le site web des cast codeurs est conforme ? API Popover https://web.dev/blog/popover-baseline?hl=en L'API Popover est maintenant disponible dans tous les navigateurs majeurs Ajoutée à Baseline le 27 janvier 2025 Permet de créer des popovers natifs en HTML, sans JavaScript complexe Exemple : Ouvrir Contenu du popover Problème initial (2024) : Bug sur iOS empêchant la fermeture des popovers Intégrer un front-end React dans une app Spring-Boot https://bootify.io/frontend/react-spring-boot-integration.html Etape par etape, comment configurer son build (https://bootify.io/frontend/webpack-spring-boot.html) et son app (controllers…) pour y intégrer un front en rect. Data et Intelligence Artificielle Traffic des sites web venant de IA https://ahrefs.com/blog/ai-traffic-study/ le AIEO apres le SEO va devenir un gros business vu que les modèles ont tendance a avoir leurs chouchous techniques ou de reference. 63% des sites ont au moins un referal viennent d'une IA 50% ChatGPT, puis plrplexity et enfin Gemini, bah et LeChat alors? 0,17% du traffic des sites vient de l'IA. Et en meme temps l'AI resume plutot que pointe donc c'est logique Granite 3.2 est sorti https://www.infoq.com/news/2025/03/ibm-granite-3-2/ IBM sort Granite 3.2, un modèle IA avancé. Meilleur raisonnement et nouvelles capacités multimodales. Granite Vision 3.2 excelle en compréhension d'images et de documents. Granite Guardian 3.2 détecte les risques dans les réponses IA. Modèles plus petits et efficaces pour divers usages. Améliorations en raisonnement mathématique et prévisions temporelles. les trucs interessants de Granite c'est sa petite taille et son cote “vraiment” open source Prompt Engineering - article détaillé https://www.infoq.com/articles/prompt-engineering/ Le prompt engineering, c'est l'art de bien formuler les instructions pour guider l'IA. Accessible à tous, il ne remplace pas la programmation mais la complète. Techniques clés : few-shot learning, chain-of-thought, tree-of-thought. Avantages : flexibilité, rapidité, meilleure interaction avec l'IA. Limites : manque de précision et dépendance aux modèles existants. Futur : un outil clé pour améliorer l'IA et le développement logiciel. QCon San Francisco - Les agents AI - Conference https://www.infoq.com/presentations/ai-agents-infrastructure/ Sujet : Infrastructure pour agents d'IA. Technologies : RAG et bases de données vectorielles. Rôle des agents d'IA : Automatiser des tâches, prévoir des besoins, superviser. Expérience : Shruti Bhat de Oracle à Rockset (acquis par OpenAI). Objectif : Passer des applis classiques aux agents IA intelligents. Défis : Améliorer la recherche en temps réel, l'indexation et la récupération. Nous concernant: Évolution des rôles : Les développeurs passent à des rôles plus stratégiques. Adaptation nécessaire : Les développeurs doivent s'adapter aux nouvelles technologies. Official Java SDK for MCP & Spring AI https://spring.io/blog/2025/02/14/mcp-java-sdk-released-2 Désormais une implémentation officielle aux côtés des SDK Python, TypeScript et Kotlin. ( https://modelcontextprotocol.io/ ) Prise en charge de Stdio-based transport, SSE (via HTTP) et intégration avec Spring WebFlux et WebMVC. Intégration avec Spring AI, configuration simplifiée pour les applications Spring Boot (different starters disponibles) Codez avec Claude https://docs.anthropic.com/en/docs/agents-and-tools/claude-code/overview Claude Code est en beta, plus de liste d'attente Un outil de codage agentique intégré au terminal, capable de comprendre votre base de code et d'accélérer le développement grâce à des commandes en langage naturel. Les fonctionnalités permettent de comprendre le code, le refactorer, tester, debugger, … Gemini Code Assist est gratuit https://blog.google/technology/developers/gemini-code-assist-free/ Pour un usage personnel. Pas besoin de compte. Pas de limite. 128k token input. Guillaume démarre une série d'articles sur le RAG (niveau avancé). Le premier sur Sentence Window Retrievalhttps://glaforge.dev/posts/2025/02/25/advanced-rag-sentence-window-retrieval/ Guillaume propose une technique qui améliore les résultats de rechercher de Retrieval Augmented Generation L'idée est de calculer des vecteurs embeddings sur des phrases, par exemple, mais de retourner un contexte plus large L'intérêt, c'est d'avoir des calculs de similarité de vector embedding qui ont de bons scores (sans dilution de sens) de similarité, mais de ne pas perdre des informations sur le contexte dans lequel cette phrase se situe GitHub Copilot edits en GA, GitHub Copilot en mode agent dans VSCode Insiders https://github.blog/news-insights/product-news/github-copilot-the-agent-awakens/ Copilot Edits permet via le chat de modifier plusieurs fichiers en même temps, ce qui simplifie les refactoring Copilot en mode agent ajoute un mode autonome (Agentic AI) qui va tout seul chercher les modifications à faire dans votre code base. “what could possibly go wrong?” Méthodologies Article d'opinion interessant sur AI et le code assistant de Addy Osmani https://addyo.substack.com/p/the-70-problem-hard-truths-about Un article de l'année dernière de Addy Osmani https://addyo.substack.com/p/10-lessons-from-12-years-at-google plusieurs types d'aide IA Ceux pour boostrapper, dun figma ou d'une image et avoir un proto non fonctionnel en quelques jours Ceux pour iterer sur du code donc plus long terme on va faire une interview sur les assistants de code IA Le cout de la vitesse de l'ia les dev senior refactur et modifie le code proposé pour se l'approprier, chnger l'architecture etc donc basé sur leur connaissance appliquer ce qu'on connait deja amis plus vite est un pattern different d'apprendre avec l'IA explore des patterns d'approche et la prospective sur le futur Loi, société et organisation Elon Musk essaie d'acheter Open AI https://www.bbc.com/news/articles/cpdx75zgg88o La réponse: “non merci mais on peut racheter twiter pour 9,74 milliars si tu veux” Avec la loi narcotrafic votée au sénat, Signal ne serait plus disponible en France https://www.clubic.com/actualite-555135-avec-la-loi-narcotrafic-signal-quittera-la-france.html en plus de légaliser les logiciels espions s'appuyant sur les failles logiciel La loi demande aux messageries de laisser l'état accéder aux conversations Donc une backdoor avec une clé etatique par exemple Une backdoor comme celle des téléphones filaires américains mis en place il y a des années et maintenant exploitée par l'espionnage chinois Signal à une position ferme, soit c'est sécurisé soit on sort d'un pays Olvid WhatsApp et iMessage sont aussi visée par exemple La loi défini la cible comme la criminalité organisée : les classiques mais aussi les gilets jaunes, les opposants au projet de Bure, les militants aidant les personnes exilées à Briançon, ou encore les actions contre le cimentier Lafarge à Bouc-Bel-Air et à Évreux Donc plus large que ce que les gens pensent. Conférences La liste des conférences provenant de Developers Conferences Agenda/List par Aurélie Vache et contributeurs : 14 mars 2025 : Rust In Paris 2025 - Paris (France) 19-21 mars 2025 : React Paris - Paris (France) 20 mars 2025 : PGDay Paris - Paris (France) 20-21 mars 2025 : Agile Niort - Niort (France) 25 mars 2025 : ParisTestConf - Paris (France) 26-29 mars 2025 : JChateau Unconference 2025 - Cour-Cheverny (France) 27-28 mars 2025 : SymfonyLive Paris 2025 - Paris (France) 28 mars 2025 : DataDays - Lille (France) 28-29 mars 2025 : Agile Games France 2025 - Lille (France) 28-30 mars 2025 : Shift - Nantes (France) 3 avril 2025 : DotJS - Paris (France) 3 avril 2025 : SoCraTes Rennes 2025 - Rennes (France) 4 avril 2025 : Flutter Connection 2025 - Paris (France) 4 avril 2025 : aMP Orléans 04-04-2025 - Orléans (France) 10-11 avril 2025 : Android Makers - Montrouge (France) 10-12 avril 2025 : Devoxx Greece - Athens (Greece) 11-12 avril 2025 : Faiseuses du Web 4 - Dinan (France) 14 avril 2025 : Lyon Craft - Lyon (France) 16-18 avril 2025 : Devoxx France - Paris (France) 23-25 avril 2025 : MODERN ENDPOINT MANAGEMENT EMEA SUMMIT 2025 - Paris (France) 24 avril 2025 : IA Data Day - Strasbourg 2025 - Strasbourg (France) 29-30 avril 2025 : MixIT - Lyon (France) 6-7 mai 2025 : GOSIM AI Paris - Paris (France) 7-9 mai 2025 : Devoxx UK - London (UK) 15 mai 2025 : Cloud Toulouse - Toulouse (France) 16 mai 2025 : AFUP Day 2025 Lille - Lille (France) 16 mai 2025 : AFUP Day 2025 Lyon - Lyon (France) 16 mai 2025 : AFUP Day 2025 Poitiers - Poitiers (France) 22-23 mai 2025 : Flupa UX Days 2025 - Paris (France) 24 mai 2025 : Polycloud - Montpellier (France) 24 mai 2025 : NG Baguette Conf 2025 - Nantes (France) 3 juin 2025 : TechReady - Nantes (France) 5-6 juin 2025 : AlpesCraft - Grenoble (France) 5-6 juin 2025 : Devquest 2025 - Niort (France) 10-11 juin 2025 : Modern Workplace Conference Paris 2025 - Paris (France) 11-13 juin 2025 : Devoxx Poland - Krakow (Poland) 12-13 juin 2025 : Agile Tour Toulouse - Toulouse (France) 12-13 juin 2025 : DevLille - Lille (France) 13 juin 2025 : Tech F'Est 2025 - Nancy (France) 17 juin 2025 : Mobilis In Mobile - Nantes (France) 19-21 juin 2025 : Drupal Barcamp Perpignan 2025 - Perpignan (France) 24 juin 2025 : WAX 2025 - Aix-en-Provence (France) 25-26 juin 2025 : Agi'Lille 2025 - Lille (France) 25-27 juin 2025 : BreizhCamp 2025 - Rennes (France) 26-27 juin 2025 : Sunny Tech - Montpellier (France) 1-4 juillet 2025 : Open edX Conference - 2025 - Palaiseau (France) 7-9 juillet 2025 : Riviera DEV 2025 - Sophia Antipolis (France) 18-19 septembre 2025 : API Platform Conference - Lille (France) & Online 23 septembre 2025 : OWASP AppSec France 2025 - Paris (France) 25-26 septembre 2025 : Paris Web 2025 - Paris (France) 2-3 octobre 2025 : Volcamp - Clermont-Ferrand (France) 6-10 octobre 2025 : Devoxx Belgium - Antwerp (Belgium) 9-10 octobre 2025 : Forum PHP 2025 - Marne-la-Vallée (France) 9-10 octobre 2025 : EuroRust 2025 - Paris (France) 16-17 octobre 2025 : DevFest Nantes - Nantes (France) 4-7 novembre 2025 : NewCrafts 2025 - Paris (France) 6 novembre 2025 : dotAI 2025 - Paris (France) 7 novembre 2025 : BDX I/O - Bordeaux (France) 12-14 novembre 2025 : Devoxx Morocco - Marrakech (Morocco) 21 novembre 2025 : DevFest Paris 2025 - Paris (France) 28 novembre 2025 : DevFest Lyon - Lyon (France) 28-31 janvier 2026 : SnowCamp 2026 - Grenoble (France) 23-25 avril 2026 : Devoxx Greece - Athens (Greece) 17 juin 2026 : Devoxx Poland - Krakow (Poland) Nous contacter Pour réagir à cet épisode, venez discuter sur le groupe Google https://groups.google.com/group/lescastcodeurs Contactez-nous via X/twitter https://twitter.com/lescastcodeurs ou Bluesky https://bsky.app/profile/lescastcodeurs.com Faire un crowdcast ou une crowdquestion Soutenez Les Cast Codeurs sur Patreon https://www.patreon.com/LesCastCodeurs Tous les épisodes et toutes les infos sur https://lescastcodeurs.com/

In this week's episode, Josh and I are discussing free agency in the NFL. More specifically we are discussing what happened between the Browns and Myles Garrett. Did Garrett sell out? Did the Browns promise something other than forty million a year? We discuss all the scenarios, plus we breakdown all of the other big moves as well. Plus, what is happening around the sports world.

In this conversation, Erik Christiansen and Larry Kim delve into the complexities of the website visitor identification industry, discussing its current state, the accuracy of data, and the implications of using such data in marketing strategies. They explore the differences between first-party and third-party data, the challenges of ensuring data accuracy, and the potential costs associated with using inaccurate data. The discussion emphasizes the need for transparency and understanding in the industry, highlighting the importance of accurate data for effective marketing.ChaptersUnderstanding Website Visitor Identification TechnologyTransparency and Accuracy in Visitor IdentificationChallenges of Data Accuracy and Its ImplicationsEstablishing a Baseline for Testing AccuracyFirst-Party vs. Third-Party DataThe Importance of Accurate Data in MarketingThe Cost of Poor Data QualityMatch Rate vs. Accuracy in Visitor IdentificationThe Dangers of Relying on Inaccurate DataIndustry Reactions and Future DirectionsConcluding Thoughts and Lessons Learned

N Engl J Med 2001;344:1879-1887Background: Acute coronary syndrome is broadly categorized into unstable angina, non-ST-elevation myocardial infarction (NSTEMI) and ST-elevation myocardial infarction (STEMI). In unstable angina, there is no rise in cardiac biomarkers, although some challenge this clinical entity in the current era of high sensitivity troponins. In NSTEMI, there is elevation of cardiac biomarkers but no ST segment elevation on the electrocardiogram. In STEMI, there is an ST segment elevation on the electrocardiogram as well as a rise in cardiac biomarkers.Cardiology Trial's Substack is a reader-supported publication. To receive new posts and support our work, consider becoming a free or paid subscriber.In patients with STEMI, percutaneous coronary intervention (PCI) significantly improves outcomes. However, its role in acute coronary syndrome without ST-segment elevation is less clear for several reasons. Patients with NSTEMI tend to be older and have more comorbidities, increasing procedural risks. This also means that they have competing risks for mortality, potentially reducing the benefit of PCI. Another key challenge is that NSTEMI patients frequently have multivessel disease, making it more difficult to identify the culprit lesion; since there is usually only partial occlusion of the culprit coronary artery. In contrast, there is usually complete occlusion of a coronary artery in STEMI and ST-segment elevation on the electrocardiogram helps localize the infarcted area, making it relatively easy to identify the culprit artery.The findings from previous randomized trials of revascularization in unstable angina and NSTEMI, have been inconsistent. The TACTICS–Thrombolysis in Myocardial Infarction 18 trial sought to compare early invasive vs conservative strategy in patients with unstable angina or NSTEMI.Patients: Eligible patients had angina within 24 hours that was: >20 minutes in duration, accelerating angina, or recurrent episodes at rest or with minimal effort. Patients also had to have one of the following: ST-segment depression of at least 0.05 mV, transient ( 2.5 mg/dL.Baseline characteristics: The trial randomized 2,220 patients – 1,114 randomized to early invasive strategy and 1,106 randomized to conservative strategy.The average age of patients was 62 years and 66% were men. Approximately 28% had diabetes and 39% had prior myocardial infarction.Troponin T levels were elevated (>0.01 ng/ml) in 54% of the patients.Procedures: Patients were randomly assigned in a 1:1 ratio to undergo early invasive vs conservative strategy.Patients received aspirin 325 mg daily, intravenous unfractionated heparin (5000U bolus, followed by an infusion at 1000U/ hour for 48 hours), and intravenous tirofiban (0.4 μg/kg/minute for 30 minutes followed by an infusion of 0.1 μg/kg/minute for 48 hours or until revascularization with tirofiban administered for at least 12 hours after PCI).Patients in the early invasive arm underwent coronary angiogram between 4 and 48 hours after randomization and underwent PCI as appropriate. Patients in the conservative arm were treated medically. If stable, they underwent an exercise-tolerance test before discharged (83% of these tests were with nuclear perfusion or echocardiography imaging). Patients in the conservative arm underwent coronary angiography with PCI if they had angina at rest associated with ischemic EKG changes or elevation in cardiac biomarkers, had clinical instability or had ischemia on their stress test.Endpoints: The primary outcome was a composite of death from any cause, nonfatal myocardial infarction, and rehospitalization for an acute coronary syndrome, at six months.The estimated sample size to provide 80% power was 1,720 patients. This assumed that 22% of the patients in the conservative arm would experience the primary outcome and that the early invasive strategy would result in 25% relative risk reduction in the primary outcome. The sample size was later increased to 2,220 patients.Results: In the early invasive strategy, 97% of the patients underwent coronary angiogram after a medium of 22 hours after randomization, and 60% underwent PCI or CABG. In the conservative arm, 51% underwent coronary angiogram and 36% underwent revascularization during the index hospitalization.The primary composite endpoint was lower with the early invasive strategy (15.9% vs 19.4%, odds ratio: 0.78, 95% CI: 0.62 - 0.97; p= 0.025). The Kaplan-Meier curves started to separate at approximately one week. This benefit was driven by lower myocardial infarction and lower rehospitalization for an acute coronary syndrome with the early invasive strategy; (4.8% vs 6.9%) and (11.0% vs 13.7%), respectively. There was no difference in all-cause death (3.3% vs 3.5%).There were 3 important subgroup interactions. First is based on ST changes where patients with ST changes at presentation had all the benefit with an early invasive strategy (16.4% vs 26.3% [for patients with ST changes] and 15.6% vs 15.3% [for patients without ST changes]). Second is based on Troponin T levels where patients with troponin T> 0.1 ng/mL had significantly more benefit with an early invasive strategy (16.4% vs 24.5% and 15.1% vs 16.6%). The third is based on TIMI score where patients with higher TIMI score had more benefit with an early invasive approach. For a high TIMI score of 5-7, the event rate was 19.5% with early invasive vs 30.6% with conservative approach. Patients with TIMI score of 0-2 had no benefit with an early invasive strategy (12.8% with early invasive vs 11.8% with conservative strategy).Note to readers: TIMI score is a risk stratification tool used to predict 14-day adverse outcomes in patients with unstable angina or NSTEMI. The score ranges from 0 to 7 with higher scores indicating worse prognosis.Conclusion: In patients with unstable angina or NSTEMI, an early invasive strategy reduced the composite endpoint of death from any cause, nonfatal myocardial infarction, and rehospitalization for an acute coronary syndrome at six months with a number needed to treat of approximately 29 patients.The subgroup analysis of this trial is particularly important and biologically plausible, as the presence of ST changes and level of cardiac biomarkers elevation indicate more significant myocardial ischemia or necrosis. Patients without ST changes comprised 62% of the study participants, while those with negative cardiac biomarkers made up 59%, and the study results should not be generalized to these subgroups.Another key consideration is the lack of detailed criteria for what was deemed ‘appropriate' revascularization. Only 60% of patients in the early invasive strategy group underwent revascularization, underscoring that not all patients with unstable angina or NSTEMI benefit from coronary angiography and that further risk stratification is necessary.Cardiology Trial's Substack is a reader-supported publication. To receive new posts and support our work, consider becoming a free or paid subscriber. Get full access to Cardiology Trial's Substack at cardiologytrials.substack.com/subscribe

Nobody wants to miss a concussion. Mind Mirror uses your cell phone to measure Pupillary Light Reaction or PLR. Glenn Bowers joins Ben Stephenson and Jeremy Jackson to discuss the new concussion tool. Artificial intelligence, mobile computing & pupillary light reflex (PLR) In 2022 Mind Mirror started because I was coaching my kids and missed a concussion with my own son. We saw an opportunity to take AI tech and pupillary light reflex to assess concussion risk within 30 seconds. Is Mindmirror used as an on-field assessment tool or a return-to-play tracking/monitoring system? Both, with the speed of the test and subjectivity taken out of the assessment, it can be a great tool for on-field assessments. It also provides an objective return-to-play measure providing clinicians with the ability to determine safe RTP without bias, subjectivity or dishonesty from patients. One study found that the PLR test isn't affected by exertion or emotions which can't be said about all of subjective tests commonly used for concussion testing.  Mind Mirror doesn't use baseline tests, so how are normative values collected? While baseline testing isn't required it is highly recommended.  Baseline testing for this model is extremely efficient, it only takes 7 seconds for each athlete to be tested and automatically stored in the system. Will be adding a roster system that can link the rosters with Healthy Roster, Rankone and other EMR software.  Could this help prevent lawsuits and protect athletic trainers when returning players with a possible brain injury? Is it lawfully sound? There is no single test to definitively determine if a brain injury has occured, we are more practically used as an objective test to determine if symptoms associated with a brain injury are present.  While most concussion testing is subjective we provide an objective measure.  What biomarkers are we testing? (like Sway tests balance, memory, and movement coordination) what makes the PLR test superior to these existing solutions?   Velocity of constriction Velocity of dilation The system calculates all 14 biomarkers and provides a probability score ranking them into 3 categories green, yellow, and red.  Green is less than 0.3 probability indicating the brain is likely healthy. Yellow is between 0.3 - 0.6 probability which is in the middle and requires further testing.   Red is above 0.6 and indicates there is a high chance that the patient has a concussion.  How was the AI software created? Iris, an old colleague from Italy had a cool idea and I knew that if we could figure out the technology this could be big.  We are already working with the U.S. military, collegiate, and high school settings. Contact Us: Mind Mirror - info@mindmirror.health Glenn Bowers - glennb@mindmirror.health Ben Stephenson - _benstephenson Jeremy - @SportsMedicineBroadcast on IG

Building a strong nutritional baseline is the key to long-term results. In this episode of Beast Over Burden, we break down the daily habits lifters need to create structure, eliminate setbacks, and stay consistent. Forging Daily Nutritional Habits: Actionable Steps Build a Routine: Establish fixed meal times, eliminate caloric drinks, and cut out mindless snacking. Prioritize Whole Foods: Create a repeatable meal plan that minimizes decision fatigue. Use Habit Stacking: Drink water before meals, prep your gym bag the night before, and link new habits to existing routines. Understand Your Triggers: Identify what leads to unhealthy choices and develop strategies to overcome them. Eliminating Detrimental Habits: Behavioral Shifts Say Goodbye To: Excessive alcohol, added fats, and hidden sugars. Practice Mindful Eating: Pay attention to hunger cues, savor meals, and eliminate distractions while eating. Embrace Cooking & Meal Prep: Control ingredients and develop a deeper connection with your food. Identify Root Causes: Recognize stress eating and social pressures, then create solutions to stay on track. Cultivating Long-Term Habits: Consistency & Tools Fuel Your Enjoyment: Find healthy meals you love and experiment with new recipes. Leverage Accountability: Track your meals, work with a coach, or join a support group. Practice Self-Compassion: Learn from mistakes and get back on track without guilt. Utilize Helpful Tools: Simplify meal prep with an Instant Pot, griddle, immersion blender, and smoker or gas grill. Build a solid nutrition foundation and fuel your performance. #NutritionForLifters #HealthyHabits #BeastOverBurden #FitnessFuel PS - IF YOU'RE INTERESTED IN TAKING ONLINE COACHING FOR A TEST RUN, CHECK IT OUT HERE.  Connect with the hosts Niki on Instagram Andrew on Instagram Connect with the show Barbell Logic on Instagram Podcast Webpage Barbell Logic on Facebook Or email podcast@barbell-logic.com

Hour 1 Audio from WGIG-AM and FM in Brunswick, GA

Ever feel like you're eating “right” but not losing weight? The truth is, most of us massively underestimate how much we eat—and that's where tracking comes in. In this episode, I'm walking you through a simple, two-week method to find your personal calorie baseline so you can finally understand what your body actually needs.I'll break down:✔️ The science behind calorie tracking and why research shows it works for weight loss✔️ Why online calorie calculators can be wildly inaccurate (and what to do instead)✔️ Step-by-step instructions for tracking without obsession✔️ How hormones like cortisol, thyroid function, and leptin impact your metabolism✔️ What it means if your calorie needs are really low—and why you shouldn't just cut more caloriesIf you've ever felt stuck or confused about why weight loss isn't happening, this episode is going to be a game-changer. Tune in now and take the guesswork out of your progress!Link to the NO-PREP, NO-COOK MEAL PLAN PDF https://heatherheynen.com/store My Website: https://www.heatherheynen.comFollow me:IG: @heynencounselingandcoachingFB: Heather HeynenYouTube: Heather Heynen WellnessLink to my Online Course: End Binge Eating, Overeating & Emotional Eating For Good (available through December 1st, 2025)mindful-eating-mastery-overcome-binge-eating-over-eating-emotional-eatingLink to my Online Course: Natural Appetite Regulation: Actionable & Simple Strategies for Weight Loss And Normalizing the Appetite (available through Dec 1st 2025)https://heather-heynen-s-school.teachable.com/p/natural-appetite-regulation-strategies-and-skills-for-weight-loss-weight-maintenanceLink to my Online Course: When You're Ready To Stop The Weight Loss Medication: A Comprehensive Guide To Natural Weight Maintenance & Mastery (Available through Dec 1st 2025)weight-maintenance-mastery-exactly-how-to-keep-the-weight-off-after-drug-based-weight-lossLink to my ebook High Protein, Easy Recipes:my-downloadable-530035Please support this show's affiliates:David Protein Bars: Highest Protein, No Sugar, Lowest Calorie, Best Tasting protein bar out there! https://davidprotein.com/HEATHERPhysiVantage: The Best Whey Protein, Collagen & Morehttps://physivantage.com/?ref=HEATHERHEYNENEnter Discount Code HEATHERHEYNEN at checkoutThorne Supplements (High Quality Supps) Get 10% off with this link:https://www.thorne.com/u/PR12562435Strands: Affordable, easy food intolerance testing for humans and pets!  https://www.5strands.com/#HeatherHeynen. Enter Discount Code HeatherHeynen at checkoutThe information in this podcast is intended to provide broad understanding and knowledge of healthcare topics. This information is for educational purposes only and should not be considered complete and should not be used in place of advice from your physician or healthcare provider. We recommend you consult your physician or healthcare professional before beginning or altering your personal exercise, diet or supplementation program.

The Pacers and Pistons are cooking up something special! We break down their surprising mid-season surge, comparing their climb to the chaos of "Breaking Bad." Howd They Pull It Off? Also this past week has been nothing short of Impressive with some of the performances coming out of the league. Find out who Impressed Us. Download and DIscuss with USBasketball season is heating up and PrizePicks is THE BEST place to get real money action while watching your favorite sports! You can now win up to 1000x your money on PrizePicks!Sign up today and get $50 instantly when you play $5! You don't even need to win to receive the $50 bonus, it's guaranteed when you use the promo code CLNS. PrizePicks also offers weekly promotions that can lead to big payouts and is available in more than 30 states, including California, Texas, Georgia and Florida.PrizePicks is truly the best way to win real money with all the various opportunities to play and collect your winnings. Due to the enormous selection of players and stat types available, we can mix and match our playing strategies based on personal preferences. I might take Jayston Tatum for more than 27 points and Jrue Holiday for more than 2 steals to mix in some defense in my selections. Do you think Steph Curry will get More than 5 3-pointers next week? Giannis for More than 35 points? Cook up hot takes with your friends and win real money this basketball season when you and your crew Run Your Game on PrizePicks.And for those who love a quick win, PrizePicks is the way to go. You can make your picks and submit your entry in less than 60 seconds! So, what are you waiting for? “Download the app today and use code CLNS to get $50 instantly after you play your first $5 lineup!”Remember, with PrizePicks, it's as simple as picking more or picking less. Again that's promo code CLNS to get $50 after you play your first $5 lineup. The Baseline is rocking with Prize Picks and you should too. “PrizePicks. Run Your Game!”Become a supporter of this podcast: https://www.spreaker.com/podcast/the-baseline-nba-podcast--3677698/support.

N Engl J Med 2024;390:1481-1492Background: In patients with ST-elevation myocardial infarction (STEMI), opening the culprit artery improves outcomes. Nearly half of STEMI patients have disease in other coronary arteries. Whether revascularizing these non-culprit arteries improves outcomes remained uncertain. The PRAMI trial showed improvement in outcomes with complete revascularization but was relatively small, included 465 patients, and did not require the use of fractional flow reserve (FFR).Cardiology Trial's Substack is a reader-supported publication. To receive new posts and support our work, consider becoming a free or paid subscriber.The FFR-Guidance for Complete Nonculprit Revascularization (FULL REVASC) trial sought to assess if FFR-guided completed revascularization improves outcomes compared to culprit-only percutaneous coronary intervention (PCI).The COMPLETE trial was not published by the time the FULL REVASC trial started enrolling patients.Patients: Eligible patients had STEMI and were undergoing PCI or had high risk NSETMI undergoing urgent PCI. High risk NSTEMI included patients with dynamic ST–T-wave changes, ongoing chest pain, acute heart failure, hemodynamic instability independent of electrocardiographic changes, or life-threatening ventricular arrhythmias.Eligible patients had to have multivessel coronary artery disease, defined as one or more lesions in a nonculprit artery with a diameter of ≥ 2.5 mm and a visually graded stenosis of 50 - 99%.Patients were excluded if they had previous CABG, left main disease or cardiogenic shock.Baseline characteristics: The trial randomized 1,542 patients – 778 randomized to culprit-only PCI and 764 randomized to complete revascularization. Patients were recruited from 32 centers in 7 countries.Approximately 91% of the patients had STEMI and 9% had high risk NSTEMI.The average age of patients was 65 years and 76% were men. Approximately 51% had hypertension, 16% had diabetes, 23% were on treatment for hyperlipidemia, 8% had prior myocardial infarction, and 35% were current smokers.The number of residual coronary arteries with stenosis of 50-99% was 1 in 72% of the patients and 2 or more in the rest.Procedures: Patients were randomly assigned in a 1:1 ratio to undergo culprit-only PCI or FFR-guide complete revascularization. The study was open label.Patients in the culprit-PCI only group did not receive further revascularization during the index hospitalization. Patients in the FFR-guided complete revascularization could receive further revascularization during the index procedure or during the index hospitalization. PCI of non-culprit lesion was recommended if FFR was 0.80 or less.Endpoints: The primary outcome was a composite of death from any cause, myocardial infarction, or unplanned revascularization. The main secondary outcomes were a composite of death from any cause or myocardial infarction and unplanned revascularizationAnalysis was performed based on the intention-to-treat principle. The estimated sample size to achieve 80% with a two-sided alpha of 0.05 was 4,052 patients. This sample size would detect 0.75 risk ratio for the composite outcome of death or myocardial infarction at 1-year assuming 9.9% event rate in the culprit-only PCI. After the publication of the COMPLETE trial, the trial was stopped early due to ethical and feasibility concerns. Consequently, the original key secondary outcome (death from any cause, myocardial infarction, or unplanned revascularization) became the new primary outcome, and events after 1 year of follow-up were included in the primary analysis.Results: The trial was stopped after randomizing 38.1% of the original sample size. Among the patients assigned to the FFR-guided complete-revascularization arm, the procedure was followed in 95.9% of the patients, and among these patients, 17.9% underwent FFR-guided complete revascularization of non-culprit lesions during the primary PCI and the rest during the index hospitalization. Among the patients assigned to culprit-only arm, the assigned strategy was followed in 99.6% of the patients. The median follow-up time was 4.8 years.FFR was 0.8 or less in 392 (47.3%) of non-culprit vessels assessed, and PCI was performed in 369 (94.1%) of these vessels. In total, PCI was performed in 18.8% of the total non-culprit vessels. The average number of stents during the index hospitalization was 1 in the culprit-only PCI group and 2 in the complete revascularization group.The primary composite outcome was not significantly different between both treatment groups (19.0% with complete-revascularization vs 20.4% with culprit-only PCI, HR: 0.93, 95% CI: 0.74 - 1.17; p= 0.53). There were also no significant differences in composite endpoint of death from any cause or myocardial infarction (16.5% with complete revascularization vs 15.3% with culprit-only PCI) or unplanned revascularization (9.2% with complete revascularization vs 11.7% with culprit-only PCI).Stent thrombosis and stent restenosis were significantly more frequent in the complete revascularization arm (2.5% vs 0.9%, HR: 2.80, 95% CI: 1.18 – 6.67) and (4.2% vs 2.3%, HR: 1.84, 95% CI: 1.03 – 3.28), respectively.Baseline risk or coronary anatomy did not significantly affect subgroup interactions for the primary outcome.Conclusion: In patients with STEMI or high risk NSTEMI, FFR-guided complete revascularization compared to culprit-only PCI, did not improve the outcomes of death from any cause, myocardial infarction, or unplanned revascularization, over a median follow up time of 4.8 years. Complete revascularization resulted in more stent thrombosis and stent restenosis.The study lost some statistical power by stopping early, resulting in a final power of 74%. We disagree with the authors' decision to halt the trial prematurely based on the findings of the COMPLETE trial. COMPLETE was the first large trial to demonstrate a benefit in hard outcomes when revascularizing stable plaques, and its results warrant further confirmation. Furthermore, COMPLETE used different strategy as FFR was not required.Note to readers: Power measures the study's ability to avoid a Type II error (false negative) and it equals 1 - β with β being the probability of a Type II error. In other words, power represents the probability of correctly rejecting the null hypothesis (H₀) when the alternative hypothesis (H₁) is true. Most clinical trials aim for 80% or 90% power. For example, a study with 80% power has a 20% risk of failing to detect a real effect.Cardiology Trial's Substack is a reader-supported publication. To receive new posts and support our work, consider becoming a free or paid subscriber. Get full access to Cardiology Trial's Substack at cardiologytrials.substack.com/subscribe

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/QZC865. CME/AAPA credit will be available until March 3, 2026.Individualizing the PBC Care Pathway: From Baseline and Beyond In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Gilead Sciences, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/QZC865. CME/AAPA credit will be available until March 3, 2026.Individualizing the PBC Care Pathway: From Baseline and Beyond In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Gilead Sciences, Inc.Disclosure information is available at the beginning of the video presentation.

Moms, let's be real—parenting is a wild ride, full of ups and downs, curveballs, and unexpected turns. But what if there was a way to make those ups and downs a little easier to handle? That's where your mental health baseline comes in. Today, I'm talking with my friend Julie Taylor, a writer, mom, and someone who just gets it. We're breaking down what a mental health baseline is, how to boost it, and why taking care of yourself isn't a luxury—it's a necessity. And trust me, Julie is the perfect person for this conversation—not only does she have a way of making deep topics feel so relatable, but she also speaks from raw, personal experience. A little over a year ago, Julie lost her infant son at birth—a loss that completely changed her understanding of resilience, grief, and what it truly means to rebuild your emotional baseline. Her wisdom comes from lived experience, and I know her perspective will resonate with so many of you. Follow Chatbooks  Follow Vanessa  Follow Julie  8:30 How to determine your baseline in mental health  14:45 Julie's experience with grief  21:00 Do what you say you're going to do for a mental health boost  23:15 Trust the times and seasons  24:10 Try something new, or return to a past hobby  26:15 Not meant to stay in survival mode  29:00 What helped Julie the most going through grief  32:30 How to choose connection with your kids that makes a difference  44:00 You're doing better than you think you are  45:30 Tell your friends the good in them  47:00 Our limitations are invitations for collaborations   

N Engl J Med 2013;369:1115-23Background: The COURAGE trial was published in 2007. It compared up-front PCI to medical therapy alone in patients with stable CAD. Preventive PCI did not reduce the chance of dying or having a heart attack over a median follow up time of 5 years. The results rocked the cardiology world because for years prior to the publication of COURAGE, the standard of care called for revascularization of obstructive coronary stenosis. Despite what we would consider minor criticisms of COURAGE, the results have held over time as a preventive PCI strategy has failed repeatedly to reduce death or MI compared to medicine alone in subsequent large trials (BARI 2D, FAME 2, ISCHEMIA and ISCHEMIA-CKD) involving patients with stable CAD. But what about patients with acute coronary syndromes who have, a clearly defined “culprit” lesion and stable coronary stenosis of a non-infarct vessel? On the surface, the answer might seem simple - treat the “culprit” lesion with PCI and leave the stable disease alone. Continue optimal medical treatment of stable CAD indefinitely with consideration of revascularization only if new symptoms arise. But what if a stable coronary stenosis behaves differently in a patient with an acute coronary syndrome than in patients without it? Are these patients predisposed or particularly susceptible to acute plaque rupture and thrombogenesis to such an extent that they would benefit from a preventive revascularization strategy? The Primary Angioplasty in Myocardial Infarction (PRAMI) trial sought to test the hypothesis that immediate preventive PCI of non-culprit vessels plus the culprit vessel compared to culprit vessel only PCI would improve outcomes in patients with a STEMI and coronary stenosis of a non-infarct related artery.Cardiology Trial's Substack is a reader-supported publication. To receive new posts and support our work, consider becoming a free or paid subscriber.Patients: From 2008 through 2013, patients were enrolled from 5 coronary care centers in the United Kingdom. Patients could be any age with acute STEMI and multivessel CAD detected at the time of emergency PCI. The trial was limited to patients with STEMI because ST-segment elevation, unlike ST-segment depression, localizes the area of ischemia in the myocardium and an “infarct-artery” is usually easy to distinguish. Clinically stable patients were considered for eligibility after undergoing PCI of the infarct artery while they were in the catheterization lab. They were eligible if successful PCI of infarct artery was performed and there was stenosis of 50% or more in one or more non-infarct arteries. Exclusion criteria included cardiogenic shock, previous CABG, had left main or significant disease in the ostia of both the LAD and circumflex vessels, or if the only non-infarct stenosis was a chronic total occlusion.Baseline characteristics: The trial screened 2,428 patients and randomized 465 patients (19%) with 234 to preventive PCI and 231 to no preventive-PCI. The majority of patients were excluded for single vessel disease (1122/1922 [58%]). The average age of patients was 62 years and more than 75% were men. Close to 50% were current smokers. The infarct artery was anterior in 35%, inferior in 60% and lateral in 5%. Approximately 65% of patients had 2 vessel disease and 35% had 3 vessel disease.Procedures: After completion of PCI in the infarct artery, eligible patients were randomized and those assigned to the preventive-PCI group underwent the procedure immediately in all non-infarct arteries with a coronary stenosis >50%. PCI was discouraged at a later date (sometimes this strategy is referred to as “staged PCI”) in the no preventive-PCI group unless it was symptom driven. Any patient in the trial with subsequent symptoms of angina that were not controlled with medicine was required to undergo objective assessment of ischemia to secure a diagnosis of refractory angina. Follow-up information was collected at 6 weeks and then yearly thereafter.Endpoints: The primary endpoint was a composite of death from cardiac causes, nonfatal MI, or refractory angina. Secondary outcomes included the individual components of the composite endpoint along with noncardiac death and repeat revascularization. Myocardial infarction was defined as symptoms of cardiac ischemia and a troponin level >99% URL. However, within 14 days after randomization, MI diagnosis also required ECG evidence of new STE or left bundle branch block and angiographic evidence of coronary artery occlusion (essentially this makes it so only in-stent thrombosis or spontaneous STEMI count and other causes of peri-procedural MI do not - this would bias the trial in favor of the preventive-PCI group).Refractory angina was defined as angina despite medical therapy and objective evidence of myocardial ischemia (i.e., ischemia on ECG during spontaneous episode of pain or abnormal results on functional testing).It was determined that 600 patients would be needed to achieve 80% power to detect a 30% relative reduction in the preventive-PCI group, at a 5% level of significance, assuming an annual rate of the primary outcome of 20% in the control group. Stopping criteria were prespecified if the results from the trial showed a primary outcome difference at the 0.001 level of significance. Results: The trial was stopped early based on a significant difference (P50%, preventive PCI significantly reduced a primary composite outcome of cardiac death, nonfatal MI and refractory angina in the PRAMI trial with an estimated NNT of 7 patients over 2 years. Individual components of the primary endpoint that were significantly reduced included nonfatal MI and refractory angina by similarly large margins. These results may seem impressive at first glance but we urge extreme caution in their interpretation. First, this is a relatively small trial with a historically large effect size, especially when considering hard endpoints like cardiac death and nonfatal MI were included. Such results are often later found to be falsely positive when larger, confirmatory studies are conducted. Second, the trial was stopped early and early stopping is prone to yield false positive and/or exaggerated results. Third, inclusion of refractory angina in the primary endpoint, an endpoint susceptible to bias in an unblinded study (see earlier discussion of “faith healing” and “subtraction anxiety” in FAME 2; consideration also must be given to nocebo effects in patients who know they have “untreated blockages”), clouds the main findings by inflating the effect size and making the trial susceptible to large differences in underpowered endpoints before sufficient data can be accumulated on hard outcomes. For example, if the trial had sought to detect a conservative difference of 30% in a primary composite endpoint that only included cardiac death or nonfatal MI, based on an event rate of 12% in the control group (the actual event rate in the trial), over 2,200 patients would be needed for 80% power at a 5% level of significance. The estimated number of actual events would be around 230. However, only 47 events occurred in PRAMI making the results highly susceptible to noise.While results of PRAMI suggest a beneficial role for preventive-PCI in patients with STEMI, more evidence is needed to confirm the results.Thanks for reading Cardiology Trial's Substack! This post is public so feel free to share it. Get full access to Cardiology Trial's Substack at cardiologytrials.substack.com/subscribe

Watch Here : https://www.youtube.com/watch?v=7BWl8mwzAbk Website: https://vigoroussteve.com/ Consultations: https://vigoroussteve.com/consultations/ eBooks: https://vigoroussteve.com/shop/ YouTube Channel: http://www.youtube.com/user/VigorousSteve/ Workout Clips Channel: https://www.youtube.com/channel/UCWi2zZJwmQ6Mqg92FW2JbiA Instagram: https://instagram.com/vigoroussteve/ TikTok: https://www.tiktok.com/@vigoroussteve Reddit: https://www.reddit.com/r/VigorousSteve/ PodBean: https://vigoroussteve.podbean.com/ Spotify: https://open.spotify.com/show/2wR0XWY00qLq9K7tlvJ000 Patreon: https://www.patreon.com/vigoroussteve

Learn practical strategies for building baseline nutrition habits that go beyond macro counting, focusing on consistent daily behaviors for sustainable health and lasting results. We dive deep into the behaviors that form the foundation of your nutritional success. Forget the complicated macro calculations for a moment; we're focusing on the daily, repeatable habits that truly make a difference. These are the routines that will empower you to build a reliable nutrition baseline, ensuring you consistently nourish your body and achieve your health goals. It's not about quick fixes or fad diets, but about establishing a sustainable lifestyle. We understand that the initial excitement of starting a new nutrition plan can fade. That's why we're focusing on behaviors that reduce decision fatigue. By creating consistent routines, you'll minimize the mental energy required to make healthy choices. This approach is crucial for long-term success, as it helps you navigate those inevitable moments when willpower is low and hunger strikes. We'll explore practical strategies to help you build these essential habits. Building Consistent, Decision-Free Routines Many people get overwhelmed by the details of weighing and measuring food. While these practices can be helpful, they're not always necessary for building a solid nutrition baseline. What's more important is establishing consistent routines that reduce the number of daily decisions you need to make. This means identifying repeatable behaviors that simplify your approach to food. Think about creating a set meal schedule or preparing a few staple dishes in advance. By having go-to options, you'll eliminate the need to constantly decide what to eat. This consistency is essential for building a reliable nutrition baseline. We'll also discuss how to develop a sense of portion control without obsessively weighing every ingredient. Learning to recognize ballpark amounts can be just as effective and far less stressful. When facing situations with less control, like social gatherings or travel, having a strong foundation of consistent behaviors is key. We'll explore strategies for maintaining your nutrition baseline in these scenarios, ensuring you can confidently make healthy choices even when your routine is disrupted. The goal is to reach a point where you feel confident in your ability to navigate any situation while staying true to your nutritional goals. Practical Food Strategies and Tradeoffs Building a healthy nutrition baseline involves understanding the foods that support your goals. We'll discuss essential food groups, focusing on prioritizing protein and carbohydrates while adjusting fats to suit your needs. Learn how to identify single-ingredient foods that offer flexibility and versatility in your meal planning. For example, a big batch of chicken breasts or ground beef can be used in a variety of ways. We'll also explore the concept of tradeoffs. Understanding that you can enjoy a fattier cut of meat if you reduce fats elsewhere in your diet is crucial for creating a sustainable plan. This flexibility allows you to enjoy your favorite foods while still maintaining a healthy balance. Discover how to incorporate spices, powdered peanut butter, cinnamon, and walnuts into your meals to add flavor and nutritional value. Having a repertoire of repeated, flexible recipes is essential for long-term success. These recipes should be easy to prepare and adaptable to your preferences and nutritional needs. Consider batch cooking or meal prepping to save time and ensure you always have healthy options available. By focusing on simple, single-ingredient foods and mastering a few key recipes, you'll be well on your way to building a strong nutrition baseline. PS - IF YOU'RE INTERESTED IN TAKING ONLINE COACHING FOR A TEST RUN, CHECK IT OUT HERE.  Connect with the hosts Niki on Instagram Andrew on Instagram Connect with the show Barbell Logic on Instagram Podcast Webpage Barbell Logic on Facebook Or email podcast@barbell-logic.com

Ever feel lost in the sea of nutrition advice? Tired of starting and stopping diets? Ditch the diet! Learn why you need a nutrition baseline and how to build one.  Your nutritional baseline is you secret to sustainable nutrition success. The key to sustainable progress isn't a quick fix, but a solid foundation. In this episode, we're diving into the concept of a nutrition baseline – your personal safe haven of healthy eating habits. The Importance of Your Nutritional Baseline This isn't about restrictive dieting; it's about establishing a consistent, enjoyable way of eating that supports your overall health and well-being. Think of it as your nutritional home base, a place you can always return to when life throws you off track. This episode will equip you with the tools to create your own personalized baseline, so you can finally achieve lasting results. Your nutrition baseline is more than just a meal plan; it's a collection of consistent habits that make healthy eating second nature. It's the set of actions you can always fall back on, providing a sense of stability and direction. This "safe zone" helps you maintain a healthy weight and body composition, not necessarily "shredded" but comfortable and thriving. It's the point where you feel good, energized, and in control of your food choices. This baseline isn't about white-knuckle restriction, but rather about making consistently good choices. It minimizes processed foods, prioritizes whole, nutrient-dense options, and helps you avoid the common pitfalls that derail so many people. Think of it as your personal nutritional reset button. Building Your Nutrition Baseline A well-defined baseline includes a rough meal plan with similar foods for each meal. For example, you might have a go-to breakfast of 4 eggs with healthy carbs. Lunch could be 6-8 ounces of lean meat with veggies and carbs, and dinner might be 10 ounces of lean protein with carbs, fats, and veggies. A typical day might also include snacks like Greek yogurt with blueberries. Flexibility is key – you can add small additions like walnuts to your yogurt or swap out chicken for fish. The core principle is consistency with a foundation of whole, minimally processed foods. The building blocks of your baseline include reliable protein sources like meat, eggs, and yogurt. Healthy carbohydrates like rice, oats, bread (whole grain when possible), and fruit are also essential. Dialing In Your Nutrition Baseline Don't forget plenty of fiber from veggies, legumes, chia seeds, and nuts. Start by focusing on protein intake, aiming for roughly 1 gram per pound of body weight as a general guideline. For individuals who are older or female, a starting point of 12-15 calories per pound of body weight, with approximately 90 grams of protein (+/- 10 grams), can be a good starting point. The remaining calories can be allocated to carbohydrates. Experiment to find whole foods you enjoy, focusing on 3-4 meals per day. A great strategy is to start with protein at each meal and build around it. Visualize your plate: protein in the form of chicken breast, carbs from rice or sweet potatoes, and fiber/veggies from broccoli. Nuts can be added to bump up calories if needed. This approach allows for easy mixing and matching. For example, chicken can be used in various dishes – Mexican, Asian, sandwiches, with rice or in a tortilla. The goal isn't to follow the exact same recipes every day, but rather to have a flexible framework of nutritious foods that you enjoy and can easily adapt to your preferences and schedule. Visualizing your macros can be helpful, but don't get too caught up in precise tracking – consistency with whole foods is the most important factor. PS - IF YOU'RE INTERESTED IN TAKING ONLINE COACHING FOR A TEST RUN, CHECK IT OUT HERE.  Connect with the hosts Niki on Instagram Andrew on Instagram Connect with the show Barbell Logic on Instagram Podcast Webpage Barbell Logic on Facebook Or email podcast@barbell-logic.com

Want to Start or Grow a Successful Business? Schedule a FREE 13-Point Assessment with Clay Clark Today At: www.ThrivetimeShow.com   Join Clay Clark's Thrivetime Show Business Workshop!!! Learn Branding, Marketing, SEO, Sales, Workflow Design, Accounting & More. **Request Tickets & See Testimonials At: www.ThrivetimeShow.com  **Request Tickets Via Text At (918) 851-0102   See the Thousands of Success Stories and Millionaires That Clay Clark Has Helped to Produce HERE: https://www.thrivetimeshow.com/testimonials/ Download A Millionaire's Guide to Become Sustainably Rich: A Step-by-Step Guide to Become a Successful Money-Generating and Time-Freedom Creating Business HERE: www.ThrivetimeShow.com/Millionaire   See Thousands of Case Studies Today HERE: www.thrivetimeshow.com/does-it-work/  

Dan breaks down five key mindset shifts for business owners in the thick of the growth grind. Inspired by Alex Hormozi's tweet on sacrifice, he explores what it really takes to succeed—reflecting on courage, relationships, and balance—with actionable takeaways to stay productive and happy. Book referenced in the episode is The Power to be Disliked (https://www.amazon.com/Courage-Be-Disliked-Phenomenon-Happiness/dp/1668065967/ref=asc_df_1668065967?mcid=0db73a9ea9f13b728a2cf3eb593e7720&hvocijid=13369597873068056788-1668065967-&hvexpln=73&tag=hyprod-20&linkCode=df0&hvadid=730432682330&hvpos=&hvnetw=g&hvrand=13369597873068056788&hvpone=&hvptwo=&hvqmt=&hvdev=c&hvdvcmdl=&hvlocint=&hvlocphy=9007527&hvtargid=pla-2281435176698&psc=1). Connect with 1000+ global founders running profitable online businesses without sacrificing their unique lifestyles @ dynamitecircle.com (http://dynamitecircle.com/). CHAPTERS (00:00:35) Hormozi's 10-year formula for success (00:04:29) “The Courage to Be Disliked” (00:11:01) Change your relationships (00:15:12) Accept your responsibility (00:16:33) Take on a six-week sprint (00:18:26) Baseline & Brenwall (00:20:50) Do it for the right reasons CONNECT Dan “at” tropicalmba dot com Ian “at” tropicalmba dot com LINKS Join the DC (http://dynamitecircle.com/) Follow us on Instagram (https://www.instagram.com/tropicalmba/) PLAYLIST Niche B2B Content = Big Revenue on YouTube (https://tropicalmba.com/episodes/b2b-content-youtube) The Unexpected Downsides of Selling Your Business (https://tropicalmba.com/episodes/exit-founders-disappointed) Is Your Biggest Expense Helping or Hurting? (https://tropicalmba.com/episodes/your-biggest-expense) Past guests on TMBA include Cal Newport, David Heinemeier Hannson, Seth Godin, Ricardo Semler, Noah Kagan, Rob Walling, Jay Clouse, Einar Vollset, Sam Dogan, Gino Wickam, James Clear, Jodie Cook, Mark Webster, Steph Smith, Taylor Pearson, Justin Tan, Matt Gartland, Ayman Al-Abdullah, Lucy Bella Simkins, Brian Balfour, Nick Huber, Mike Michalowicz, Greg Crabtree, Jordan Gal